Figure 3.
Kaplan-Meier curves from the PARADIGM-HF trial for the primary composite endpoint of cardiovascular death or first hospitalization for heart failure (A), death from cardiovascular causes (B), first hospitalization for heart failure (C), and death from any cause (D). LCZ696 is valsartan/sacubitril. Reproduced with permission from the publisher. Copyright © 2014, Massachusetts Medical Society. All rights reserved.